allogeneic anti-CD38 DAR-T cells STI-1492

{
  "id": "MLC-T-ONC-009819",
  "term": "allogeneic anti-CD38 DAR-T cells STI-1492",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of human allogeneic T lymphocytes that are gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to disrupt the expression of endogenous T-cell receptor (TCR) alpha and to express a dimeric antigen receptor (DAR) composed of a fragment antigen-binding variable region (Fab) recognizing the tumor-associated antigen (TAA) cluster of differentiation 38 (CD38), linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, allogeneic anti-CD38 DAR-T cells STI-1492 are directed to and induce selective toxicity in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis. The disruption of endogenous TCR alpha prevents graft-versus-host disease (GvHD).",
  "synonyms": [
    "allogeneic anti-CD38 dimeric antigen receptor-expressing T lymphocytes STI-1492",
    "anti-CD38 A2 KOKI DAR allogeneic T cells STI-1492",
    "allogeneic anti-CD38 A2 KOKI DAR T cells STI-1492",
    "allogeneic second generation anti-CD38 Knock-out knock-in dimeric antigen receptor-4-1BB-CD3zeta-expressing T cells STI-1492"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/allogeneic-anti-cd38-dar-t-cells-sti-1492/"
}